CN101139632A - Reagent case for lung carcinoma susceptibility detection through XRCC1 gene and PARP1 gene - Google Patents
Reagent case for lung carcinoma susceptibility detection through XRCC1 gene and PARP1 gene Download PDFInfo
- Publication number
- CN101139632A CN101139632A CNA2006100309491A CN200610030949A CN101139632A CN 101139632 A CN101139632 A CN 101139632A CN A2006100309491 A CNA2006100309491 A CN A2006100309491A CN 200610030949 A CN200610030949 A CN 200610030949A CN 101139632 A CN101139632 A CN 101139632A
- Authority
- CN
- China
- Prior art keywords
- gene
- test kit
- snp site
- xrcc1
- lung cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a reagent box for detecting lung cancer susceptibility. The reagent box comprises a pair of specificity primers for detecting concurrently no. rs25487 SNP site of XRCC1 gene and no. rs1136410 SNP site of PARP1 gene, a specificity fluorescent probe and an ordinary assembly for fluorescent quantitative PCR detection. The reagent box predicts the susceptibility of individuals on lung cancer by detecting and analyzing currently the type of carried gene at SNPs site of individual XRCC1 and PARP1 gene.
Description
Technical field
The present invention relates to the test kit that a kind of disease susceptibility detects usefulness, especially a kind of test kit of detection of lung cancer susceptibility, by detecting staggered complementary gene 1 (the X-ray repair cross-complementing gene 1 that repairs of X ray simultaneously, XRCC1) single nucleotide polymorphism (SNP) site and poly ADP ribose transferring enzyme family member 1 (poly (ADP-ribose) polymerase family, member 1, PARP1 is abbreviated as ADPRT again) mononucleotide polymorphism site predict individual susceptibility to lung cancer.
Background technology
Primary bronchogenic carcinoma of lung is called for short lung cancer, is one of modal malignant tumour in our times various places, is the disease of a kind of serious threat human health and life.Tumour cell comes from tunica mucosa bronchiorum or body of gland, and regional lymphoglandula and hematogenous metastasis are often arranged, and respiratory symptoms such as irritable cough, sputum mixed with blood are often arranged in early days, and disease progression speed is relevant with the biological nature of cell.
Since half a century, the sickness rate of countries in the world lung cancer and case fatality rate all have and obviously increase trend.The World Health Organization's year 2000 report: totally 706.5 ten thousand people of malignant tumour are died from the whole world in 1997, account for 12.6% of death toll, and wherein lung cancer accounts for 19% of malignant tumour death, occupies first of the malignant tumour cause of the death.China sample survey in 1990～1992 years shows, in the tumor mortality of urban population, lung cancer rises to the 1st by original the 4th, and rising the fastest on the rural area also is lung cancer.The lung cancer morbidity rate of Yunnan tin ore is to be to rise to 219.10/10 ten thousand in the period of 197.87/10 ten thousand, 1970～1979 in the period of 28.02/10 ten thousand, 1960～1969 between 1954～nineteen fifty-nine, and this also is rare in the whole world.The famous oncologist R.Peto prophesy of Britain: if untimely control smoking of China and atmospheric pollution will become the first in the world lung cancer big country above 1,000,000 to the annual lung cancer of China in 2025.
The cause of disease and pathogenesis are not clear and definite as yet so far.Consistently think that the morbidity of lung cancer is relevant with following factors: 1. smoking (comprising initiatively smoking and passive smoking); 2. professional carcinogen, the occupational factor that causes Human Lung Cancer that has been identified comprise the polycyclic aromatic hydrocarbons in asbestos, inorganic arsenic chemicals, dichlormethyl ether, chromium and compound thereof, nickel, radon, yperite, vinylchlorid, coal smoke, tar and the oil, the heating product of tobacco etc.; 3. atmospheric pollution (comprising the pollution of indoor subenvironment and outdoor overall situation); 4. ionizing rays; 5. the presentation of results that the perspective crowd that diet and nutrition, USA New York and Chicago are carried out observes, in the food intake of natural vitamin A class, beta carotene and after the more than ten years cancer be negative correlation, wherein the most outstanding is lung cancer; 6. other, ACS classifies tuberculosis as one of pathogenic factors of lung cancer.It is 10 times of normal population that tuberculosis patient suffers from risk of lung cancer.Its main histological type is a gland cancer.In addition, factors such as virus infection, mycotoxins (flavus), body's immunity are low, endocrine disturbance and familial inheritance may also play certain comprehensive action to the generation of lung cancer.
In recent years studies show that the inactivation of the generation of lung cancer and activation of some oncogene and cancer suppressor gene is closely related.Verified several oncogene family comprises bcl-2, Kit that the ras family of mutagenesis, the myc family of amplifying gene, C-erB2, mechanism are not clear and by antioncogene p53, the p16 of wild-type variation and RB etc.Studies show that in a large number C-myc, L-myc, N-myc and RAF all have overexpression in small cell lung cancer.The then overexpression of Chang Kejian ras family gene in the nonsmall-cell lung cancer.These deep researchs will and be treated lung cancer and provide fundamental basis for the gene prevention.
SNP (single nucleotide polymorphism), promptly the single nucleotide polymorphism mark is the dna polymorphism that a class causes based on single nucleotide variation, is called third generation genetic marker by hereditary educational circles.Mainly be meant the dna sequence polymorphism that causes by the variation on the genome nucleotide level, comprise single base conversion, transversion, and the insertion/disappearance of single base etc.It is a class polymorphism mark that the most extensively exists in the genome, accounts for about 90%.The variation of these genome sequences can cause the difference of phenotype between individuality and Different Individual to disease, particularly the susceptibility of complex disease and to the difference of environmental factors, drug reaction.
XRCC1 is positioned at karyomit(e) 19q13.2-13.3 position No. 19, total length 32.3kb, and mRNA total length 2087bp has 17 exons, 634 the amino acid whose albumen of encoding.The XRCC1 encoded protein can play the effective for repairing effect to the dna single splitting of chain that causes because of ionizing rays and alkylide, by with dna ligase III, polymerase beta, poly ADP ribose transferring enzyme interaction, (Base Excision Repair, BER) path are repaired in the base excision that participates in DNA.Numerous studies show that, the polymorphism in site, XRCC1 gene top has confidential relation with cancer.The cancer relevant with XRCC1 mainly contains: mammary cancer, squamous cell carcinoma of the head and neck, the esophageal carcinoma, cancer of the stomach, colorectal carcinoma, carcinoma of the pancreas, lung cancer etc.
Rs25487 is that to be positioned at No. 19 G/A on the chromosome x RCC1 gene polymorphic, causes that the 399th amino acid of albumen of XRCC1 genes encoding becomes Gln by Arg.Arg399Gln is positioned at exon No. 10, XRCC1 protein B CRTI zone.This polymorphic frequency distribution in world crowd, G accounts for 0.72, and A accounts for about 0.28.Distribution G in the Chinese population is 0.68, and A is 0.32.Molecular biology research shows, the alternative reinforcement XRCC1 albumen of No. 399 amino acid Arg-Gln and the binding ability of DNA-carcinogens adducts on the XRCC1 gene, thereby the individual tumor susceptibility of influence.For the lung cancer case control study of large-scale crowd, the 399 amino acid mutation sites of XRCC1 take place relevant with lung cancer when doing single factor analysis by in a large number.
The PARP1 gene is positioned at karyomit(e) 1q41-q42 position No. 1, total length 47.3kb, and mRNA total length 3861bp has 23 exons, the 1015 amino acid whose poly ADP ribose transferase proteins of encoding.This kind of enzyme is revised multiple nucleoprotein by poly-ADP ribosylation reaction.This correction participates in multiple important cellular activity based on DNA, for example: differentiation, propagation, metastases etc. also participate in the activity of molecular level simultaneously, for example DNA plerosis damaged cells or the like.The major function of PARP1 is described to 3 aspects usually: 1.DNA repairing effect (BER); 2. suppress transcribing of damaged dna; 3. exhaust the energy in the cell, cause apoptosis; 4. participate in the transcriptional control of portion gene.These functions can repair cell in impaired DNA, suppress transcribing of damaged DNA, even kill the cell that can't repair, reach the effect that cancer takes place that suppresses.Discover that the PARP1 afunction can improve mammary cancer, the sickness rate of cancers such as lung cancer.
Rs1136410 is that to be positioned on the number one karyomit(e) T/C on the PARP1 gene polymorphic, causes that the 762nd amino acid of albumen of PARP1 genes encoding becomes Ala by Val.This polymorphic frequency distribution among the world crowd that NCBI announces, T accounts for 0.808, and C accounts for about 0.192, and heterozygosity is 0.311.Molecular biology research shows that last No. 762 amino acid of PARP1 are converted into Ala by Val, have reduced the activity of enzyme, causes the occurrence risk of multiple cancer to raise.The association analysis of the Chinese population of large sample shows that the polymorphism in this site is one of lung cancer influence factor important in the Chinese population.
A large amount of association analysis both domestic and external shows that the lung cancer incidence increased when the rs25487 SNP loci gene type on the XRCC1 gene was A; The lung cancer morbidity probability increased when rs1136410 SNP loci gene type was C on the PARP1 gene.The polymorphism in these two SNPs sites can be used for assessing individual susceptibility to lung cancer.
Summary of the invention
Polymorphism based on rs1136410 SNP site on rs25487 SNP site on the XRCC1 gene and the PARP1 gene can be used for assessing on the basis of individuality to the susceptibility of lung cancer, the invention provides a kind of test kit of detection of lung cancer susceptibility.
This test kit comprises: the Auele Specific Primer that detects the rs25487 SNP site on the XRCC1 gene is to reaching the specificity fluorescent probe, detecting the Auele Specific Primer in rs1136410 SNP site on the PARP1 gene to reaching specificity fluorescent probe, Taq enzyme, dNTP mixed solution, MgCl
2Solution, quantitative fluorescent PCR reaction buffer, deionized water.
Auele Specific Primer described in this test kit designs being meant at rs1136410 SNP site on rs25487 SNP site on the XRCC1 gene and the PARP1 gene, and the primer of dna fragmentation that can specific amplification goes out to harrow the site is right.Design this class primer to being that those skilled in the art can be unlabored.Preferably, comprise in the test kit primer with sequence shown in SEQ ID NO:1 and 2 to and have a SEQ ID
The primer of sequence is right shown in the NO:3 and 4.Auele Specific Primer synthesizes the synthetic technology of available routine.Those skilled in the art will appreciate that primer of the present invention is not limited to this two pairs of primers.
Specificity fluorescent probe described in this test kit is meant at rs1136410 SNP site on rs25487 SNP site on the XRCC1 gene and the PARP1 gene and designs, can go out the probe of these two SNPs site lung cancer tumor susceptibility gene types by the fluorescent quantitative PCR technique specific detection.Designing this class probe is that those skilled in the art can be unlabored.Preferably, comprise Taqman probe in the test kit with sequence shown in SEQ ID NO:5 and 6.The specificity fluorescent probe can synthesize with the synthetic technology of routine.Those skilled in the art can understand, specificity fluorescent probe of the present invention is not limited to this two probes, and all probes that can be used for rs1136410 SNP site on rs25487 SNP site on the fluorescence quantitative PCR detection XRCC1 gene and the PARP1 gene all within the scope of the present invention.
The component and the content of test kit of the present invention comprise:
1 μ l 10X quantitative fluorescent PCR reaction buffer,
0.1 μ l 25mM dNTP mixed solution,
0.5 μ l 25mM MgCl
2Solution,
0.02 μ l (5uni ts/ μ l) Taq archaeal dna polymerase,
20 μ M Auele Specific Primers are to (four) each 0.225 μ l,
Each 0.25 μ l of 10 μ M specificity fluorescent probes (two),
Deionized water 4.98 μ l.
This test kit detects for a person-portion and uses, and the storage temperature of test kit is-20 ℃.
Embodiment
Below in conjunction with specific embodiment, further set forth the present invention.The experimental technique of unreceipted actual conditions in the following example, usually according to normal condition, or the condition of advising according to manufacturer.
The use of embodiment 1. detection kit
The extraction of step 1:DNA template
Genomic dna with silica gel adsorption extracting mouth epithelial cells.
Step 2: quantitative fluorescent PCR reaction
But use the fluorescent quantificationally PCR detecting kit of detection of lung cancer susceptibility, wherein, contain following primer to and fluorescent probe:
It is 56 ℃ that adopted primer 1:5 '-TAACTGGCATCTTCACTTCT-3 ' (SEQ ID NO:1) Tm value is arranged
Antisense primer 1:5 '-TCCAGATTCCTGGCATTGC-3 ' (SEQ ID NO:2) Tm value is 58 ℃
It is 58 ℃ that adopted primer 2: 5 '-TTTGCCATTCACTGTGTTGG-3 ' (SEQ ID NO:3) Tm value is arranged
Antisense primer 2:5 '-ATCCTTGCTGCTATCATCA-3 ' (SEQ ID NO:4) Tm value is 54 ℃
Fluorescent probe 1:5 '-CGGCTGCCCTCCCAGAGG-3 ' (SEQ ID NO:5) Tm value is 64 ℃
Fluorescent probe 2:5 '-CAGGCCAAGGCGGAAATGCT-3 ' (SEQ ID NO:6) Tm value is 64 ℃
Adopted primer 1 is arranged, and antisense primer 1 and fluorescent probe 1 are specifically at the rs25487 SNP loci polymorphism that detects on the XRCC1 gene;
Adopted primer 2 is arranged, and antisense primer 2 and fluorescent probe 2 are specifically at detecting rs1136410 SNP loci polymorphism on the PARP1 gene.
The quantitative fluorescent PCR reaction system is cumulative volume 10 μ l, and comprising concentration is dna profiling 2 μ l, 1 μ l 10X quantitative fluorescent PCR reaction buffer, 0.1 μ l 25mM dNTP mixed solution, the 0.5 μ l 25mM MgCl of 20ng/ μ l
2The antisense primer 1 that adopted primer 1 and 2 each 0.225 μ l, 20 μ M are arranged of solution, 0.02 μ l (5units/ μ l) Taq archaeal dna polymerase, 20 μ M and the fluorescent probe 1 of 2 each 0.225 μ l, 10 μ M and 2 each 0.25 μ l, deionized water 4.98 μ l.
React on ABI9700 type pcr amplification instrument, reaction conditions is 50 ℃, 2 minutes, 95 ℃, 10 minutes, carries out 95 ℃ of 60 round-robin, 30 seconds, 60 ℃, 1 minute.Reaction finishes the back and read the fluorescent amount on ABI7900 type quantitative real time PCR Instrument.
Step 3:SNP gene type assay
The final sample fluorescence volume and the normal control that show on the quantitative real time PCR Instrument are compared, the final fluorescent signal of fluorescent probe 1 is apparently higher than normal control, illustrate that the rs25487 SNP loci gene type on the XRCC1 gene of detected DNA carries the A type, is lung cancer susceptible type; The final fluorescent signal of fluorescent probe 2 is apparently higher than normal control, illustrates that rs1136410 SNP loci gene type carries the C type on the PARP1 gene of detected DNA, is lung cancer susceptible type.
Embodiment 2. instructs people initiatively to prevent the service of lung cancer
Carried out this service in Shanghai Zhujian Biological Engineering Co., Ltd at present.
Step 1:DNA extracts
The detected person is served preceding consulting, sign Informed Consent Form, fill in living and diet custom questionnaire by the detected person.Using the oral cavity sampling to wipe away according to the indication in the sampling box carries out the mouth epithelial cells sampling, adopts silica gel adsorption to carry out the DNA extracting of mouth epithelial cells.
Step 2: genotype tests
Use test kit provided by the invention, fluorescence quantitative PCR detection is carried out in rs1136410 SNP site on rs25487 SNP site on the XRCC1 gene of detected person DNA and the PARP1 gene simultaneously, determine the genotype in these two SNPs sites.
Step 3: instruct people initiatively to prevent lung cancer
By to the genotypic analysis of detected person SNPs, provide genotype tests report and the report of detected person's individuation health guidance.The gene test report describes the height of detected person's lung cancer susceptible degree and ill probability size in detail.The report of individuation health guidance is based on detected person's genotype tests result, in conjunction with its living and diet custom survey result, the relative risk of assessment detected person lung cancer inheritance susceptible.Make the personalized healthy action scheme that is directed to the detected person simultaneously, scheme is included in the recommendation on improvement on food habits, the mode of life etc., and popularizes the health knowledge of prevention lung cancer for the detected person.
Sequence table
＜110〉Shanghai Zhujian Biological Engineering Co., Ltd
＜120〉a kind of test kit by XRCC1 gene and PARP1 gene test lung cancer susceptibility
<160>6
<210>1
<211>20
<212>DNA
＜213〉artificial sequence
<220>
＜223〉primer
<400>1
taactggcat?cttcacttct 20
<210>2
<211>19
<212>DNA
＜213〉artificial sequence
<220>
＜223〉primer
<400>2
tccagattcc?tggcattgc 19
<210>3
<211>20
<212>DNA
＜213〉artificial sequence
<220>
＜223〉primer
<400>3
tttgccattc?actgtgttgg 20
<210>4
<211>19
<212>DNA
＜213〉artificial sequence
<220>
＜223〉primer
<400>4
atccttgctg?ctatcatca 19
<210>5
<211>18
<212>DNA
＜213〉artificial sequence
<220>
＜223〉probe
<400>5
cggctgccct?cccagagg 18
<210>6
<211>20
<212>DNA
＜213〉artificial sequence
<220>
＜223〉probe
<400>6
caggccaagg?cggaaatgc?t 20
Claims (6)
1. the test kit of a detection of lung cancer susceptibility comprises: the Auele Specific Primer that detects rs1136410 SNP site on rs25487 SNP site on the XRCC1 gene and the PARP1 gene simultaneously to and specificity fluorescent probe, Taq enzyme, dNTP mixed solution, MgCl
2Solution, quantitative fluorescent PCR reaction buffer, deionized water.
2. test kit according to claim 1, it is characterized in that: described Auele Specific Primer designs being meant at rs1136410 SNP site on rs25487 SNP site on the XRCC1 gene and the PARP1 gene, and the primer that can specific amplification goes out to comprise the dna fragmentation in rs1136410 SNP site on rs25487 SNP site on the XRCC1 gene and the PARP1 gene is right.
3. test kit according to claim 1, it is characterized in that: described specificity fluorescent probe is meant at rs1136410 SNP site on rs25487 SNP site on the XRCC1 gene and the PARP1 gene and designs, can go out the probe of these two SNPs site lung cancer tumor susceptibility gene types by the fluorescent quantitative PCR technique specific detection.
4. test kit according to claim 1 is characterized in that: contained Auele Specific Primer to be selected from primer with sequence shown in SEQ ID NO:1 and 2 to and to have a primer of sequence shown in SEQ ID NO:3 and 4 right.
5. test kit according to claim 1 is characterized in that: contained specificity fluorescent probe is selected from the Taqman probe with sequence shown in SEQ ID NO:5 and 6.
6. test kit according to claim 1 is characterized in that: the component of test kit and content comprise 1 μ l 10X quantitative fluorescent PCR reaction buffer, 0.1 μ l 25mM dNTP mixed solution, 0.5 μ l 25mM MgCl
2Solution, 0.02 μ l (5units/ μ l) Taq archaeal dna polymerase, 20 μ M Auele Specific Primers are to (four) each 0.225 μ l, and 10 μ M specificity fluorescent probes (two) are 0.25 μ l respectively, deionized water 4.98 μ l.This test kit detects for a person-portion and uses, and the storage temperature of test kit is-20 ℃.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2006100309491A CN101139632A (en) | 2006-09-08 | 2006-09-08 | Reagent case for lung carcinoma susceptibility detection through XRCC1 gene and PARP1 gene |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2006100309491A CN101139632A (en) | 2006-09-08 | 2006-09-08 | Reagent case for lung carcinoma susceptibility detection through XRCC1 gene and PARP1 gene |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101139632A true CN101139632A (en) | 2008-03-12 |
Family
ID=39191737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2006100309491A Pending CN101139632A (en) | 2006-09-08 | 2006-09-08 | Reagent case for lung carcinoma susceptibility detection through XRCC1 gene and PARP1 gene |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101139632A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112410433A (en) * | 2020-12-15 | 2021-02-26 | 延边大学 | SNP (Single nucleotide polymorphism) site related to lung cancer curative effect, primer set, kit and application |
-
2006
- 2006-09-08 CN CNA2006100309491A patent/CN101139632A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112410433A (en) * | 2020-12-15 | 2021-02-26 | 延边大学 | SNP (Single nucleotide polymorphism) site related to lung cancer curative effect, primer set, kit and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Niessen et al. | Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome | |
| Wagenlehner et al. | The role of inflammation and infection in the pathogenesis of prostate carcinoma | |
| Catto et al. | Differential expression of hMLH1 and hMSH2 is related to bladder cancer grade, stage and prognosis but not microsatellite instability | |
| Barrans et al. | Whole genome expression profiling based on paraffin embedded tissue can be used to classify diffuse large B‐cell lymphoma and predict clinical outcome | |
| Kim et al. | High microsatellite instability predicts good prognosis in intestinal‐type gastric cancers | |
| Xie et al. | TERT promoter mutations and gene amplification: promoting TERT expression in Merkel cell carcinoma | |
| Mandal et al. | Polymorphic variants of DNA repair gene XRCC3 and XRCC7 and risk of prostate cancer: a study from North Indian population | |
| Watanabe et al. | EGFR mutation analysis of circulating tumor DNA using an improved PNA-LNA PCR clamp method | |
| Hlady et al. | Initiation of aberrant DNA methylation patterns and heterogeneity in precancerous lesions of human hepatocellular cancer | |
| CN101153846A (en) | Reagent kit for detecting lung cancer susceptibility through 5 SNPs of different genes | |
| El Jellas et al. | Associations between ABO blood groups and pancreatic ductal adenocarcinoma: influence on resection status and survival | |
| Di et al. | Whole exome sequencing reveals intertumor heterogeneity and distinct genetic origins of sporadic synchronous colorectal cancer | |
| Li et al. | Patient‐derived upper tract urothelial carcinoma organoids as a platform for drug screening | |
| Gao et al. | Impact of AhR, CYP1A1 and GSTM1 genetic polymorphisms on TP53 R273G mutations in individuals exposed to polycyclic aromatic hydrocarbons | |
| Sonu et al. | Optimal molecular methods in detecting p190 BCR-ABL fusion variants in hematologic malignancies: a case report and review of the literature | |
| CN101139632A (en) | Reagent case for lung carcinoma susceptibility detection through XRCC1 gene and PARP1 gene | |
| CN101153324A (en) | Reagent kit for detecting susceptibility of cancer of the lungs with SNPs of gene XRCC1 etc. | |
| CN101139631A (en) | Reagent case for lung carcinoma susceptibility detection through SNPs locus of XRCC1 gene and ERCC2 gene | |
| CN101130811A (en) | Reagent kit for detecting lung cancer susceptibility by XRCC1 gene | |
| CN101139629A (en) | Reagent case for lung carcinoma susceptibility detection through PARP1 gene | |
| CN101153345A (en) | Reagent kit for detecting susceptibility of cancer of the lungs with SNPs of gene XRCC1 and ERCC2 | |
| CN101144101A (en) | Kit for detecting lung cancer susceptibility by two different SNPs of ERCC2 gene | |
| CN101139630A (en) | Reagent case for lung carcinoma susceptibility detection through XRCC1 gene and ERCC2 gene | |
| CN101144104A (en) | Kit for detecting lung cancer susceptibility by PARP1 gene, ERCC2 gene and XRCC1 gene | |
| CN101140229A (en) | Reagent kit for detecting pulmonary cancer susceptibility with XRCC1 gene and CYP1A1 gene |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20080312 |